(Reuters) Preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy and Infectious Diseases (NIAID), could come even sooner, lead researcher Dr. Andre Kalil told Reuters in an interview.
The NIAID trial is a randomized, double-blind study in which half the patients were given the drug and the other half a placebo. Enrollment in the trial closed on Sunday, but has far exceeded initial goals of 400 to 500 patients, he said. The investigator would not disclose total enrollment, but the latest public update says trial size may exceed 800 patients. “We are looking for not only a statistical difference, but also for a meaningful clinical improvement,” he said. “We expect to have results sometime from mid- to late May.”
https://www.reuters.com/article/us-health-coronavirus-gilead-exclusive-idUSKCN2262X3
(Reuters) Preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy and Infectious Diseases (NIAID), could come even sooner, lead researcher Dr. Andre Kalil told Reuters in an interview.
The NIAID trial is a randomized, double-blind study in which half the patients were given the drug and the other half a placebo. Enrollment in the trial closed on Sunday, but has far exceeded initial goals of 400 to 500 patients, he said. The investigator would not disclose total enrollment, but the latest public update says trial size may exceed 800 patients.
“We are looking for not only a statistical difference, but also for a meaningful clinical improvement,” he said. “We expect to have results sometime from mid- to late May.”
这药本身就是开发出来治疗依波拉病毒的，结果疗效太差，变成了废药， 现在纯粹说死马当作活马医。 或者说 股票的韭菜们慢慢来，至少撑到五月 六月 七月
2月揭盲是中国的试验吗？那个试验完全没意义吧
美国这个试验是2月才开始enroll
也可能像中国发现的和对照组比没有疗效，副作用大，提前终止。
同意这个
能有些作用就已经不错了，还要啥自行车？